CVS Health Corporation (CVS)
Deutsche upgrades CVS to Buy with earnings, valuation at trough
Deutsche Bank analyst George Hill upgraded CVS Health to Buy from Hold with an unchanged price target of $66. The firm believes both the company's earnings and multiple are now likely near trough levels. CVS has taken steps to turn the company towards improving profitability, the analyst tells investors in a research note. Following an analysis of the managed care segment, Deutsche thinks an earnings recovery is both achievable and will outpace Street expectations.
Is CVS Health Stock a Buy?
CVS Health (CVS -0.18%) has been a long-running migraine for shareholders, struggling to manage rising medical costs that have impacted profitability. At the time of writing, the stock is down 25% year to date and more than 40% lower than its record-high price of $101.29 set in February 2022.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Billionaire Israel Englander Bought This High-Yield Dividend Stock Hand Over Fist in Q3. Should You Buy It Too?
Israel "Izzy" Englander's net worth tops $14 billion. He doesn't need dividend income.
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
CVS Health Corporation (CVS) Wolfe 2024 Healthcare Conference (Transcript)
CVS Health Corporation (NYSE:CVS ) Wolfe 2024 Healthcare Results Conference November 19, 2024 10:20 AM ET Company Participants Tom Cowhey - Executive Vice President, Chief Financial Officer Conference Call Participants Justin Lake - Wolfe Research Justin Lake Got to mention Larry McGrath, the head of strategy in IR refused to sit up here with us, but he's doing God's work for the company, and we all appreciate it. Thank you, Larry.
CVS Health Taps Physician To Lead Healthcare Delivery Business
CVS Health elevated Dr. Sreekanth Chaguturu to lead the company's healthcare delivery business a year after the company spent more than $20 billion on homecare provider Signify Health and senior clinic operator Oak Street Health.
Glenview Capital CEO Larry Robbins on the deal for new CVS Health board seats
Larry Robbins, Glenview Capital Management CEO, joins CNBC's 'Squawk on the Street' to discuss his firm's four new seats on the board at CVS, how the company can recover after a long decline, and more.
CVS Health adds four new board members in deal with Glenview Capital
CNBC's David Faber reports on news from CVS.
CVS Health Adds Four Board Seats In Deal With Hedge Fund
CVS Health Monday said four new members will be added to its board from the hedge fund Glenview Capital Management, an activist investor that had been pushing for changes at the diversified healthcare giant.
CVS strikes deal with activist Glenview Capital for four board seats
CVS Health struck a deal with dissident Glenview Capital giving the investor four board seats. Glenview had been pushing for changes at the healthcare giant and had met with former CEO Karen Lynch prior to her ouster.
